Treatment with interleukin (IL)-5/IL-5 receptor antibodies in patients with severe eosinophilic asthma and COPD.
Nora DrickJan FugeBenjamin SeeligerMilan SpethJens Vogel-ClaussenTobias WelteHendrik SuhlingPublished in: ERJ open research (2022)
Anti-eosinophilic therapy with interleukin-5/interleukin-5-receptor antibodies shows clinical efficacy in patients with SEA and COPD comparable to treatment response in patients with SEA alone.